Downloads

Complete publication
(PDF, 810.48 KB)

Summary
(PDF, 38.19 KB)

Request for advice
(PDF, 17.68 KB)

Status

Published, January 22nd 2014

Principal

VWS

Keywords

breast cancer
mass Screening
risk stratification
age limit
benefit Risk Ratio
overdiagnosis
false positive
overtreatment
false negative
interval Cancer
Population screening for breast cancer: expectations and developments

The Dutch population screening programme for breast cancer results in less women dying of breast cancer, because breast cancers are traced and treated earlier. The most important disadvantage of screening for breast cancer is, that it can lead to unnecessary treatment. In part due to the well organised Dutch screening programme, the advantages outweigh the disadvantages. Still, the screening programme can be improved on several issues. This writes the Dutch Health Council in a recommendation to the Minister of Health, Welfare and Sport.

Committee

  • Prof. dr. J.J.M. van Delden, MD, PhD, Professor of Medical Ethics, University Medical Center Utrecht, Utrecht, chairman
  • Prof. dr. J. Gussekloo, MD, PhD, Professor of General Medicine, Leiden University Medical Center, Leiden,
  • Dr. E.M.M. Adang, Health Economist, Radboud University Medical Center, Nijmegen
  • Dr. M.M. Boere-Boonekamp, MD, PhD, Physician, University Twente, Enschede
  • Prof. dr. M.C. Cornel, MD, PhD, Professor of Community Genetics and Public Health Genomics, VU Medisch Centrum, Amsterdam
  • Dr. W.J. Dondorp, PhD, Ethicist, Maastricht University Medical Centre, Maastricht
  • Prof. mr. J.C.J. Dute, PhD, Professor of Health Law, Radboud University, Nijmegen
  • Prof. dr. L.P. ten Kate, MD, PhD, Emeritus professor in Clinical Genetics, VU University Medical Centre, Amsterdam
  • Prof. dr. I.M. van Langen, MD, PhD, Professor of Clinical Genetics, University Medical Center Groningen
  • Prof. dr. B.J.C. Middelkoop, MD, PhD, Professor of Public Health, Leiden University Medical Center, Leiden
  • Mr. dr. M.C. Ploem, PhD, Lecturer of Health Law, Academic Medical Center, Amsterdam
  • Prof. dr. A.M. Stiggelbout, MD, PhD, Professor of Medical Decision Making, Leiden University Medical Center
  • W.A. van Veen, MD, Delft,
  • Prof. dr. G.J. van der Wilt, PhD, Professor of Health Technology Assessment, Radboud university medical center, Nijmegen
  • Dr. C.H. van Gils, PhD, Epidemiologist, University Medical Center Utrecht
  • Prof. dr. A.L.M. Verbeek, MD, PhD, Professor of Clinical Epidemiology, Radboud university medical center, Nijmegen
  • Mr. A. Rendering, LLM, Ministry for Health, Welfare and Sport, The Hague, observer
  • Dr. S.J.W. Kunst, MD, PhD, Health Council of Netherlands, The Hague, scientific secretary
  • Dr. L.G.M. van Rossum, PhD, Epidemiologist, Health Council of Netherlands, The Hague, scientific secretary

This publication may be cited as follows

Health Council of the Netherlands. Population screening for breast cancer: expectations and developments. The Hague: Health Council of the Netherlands, 2014; publication no. 2014/01. ISBN 978-90-5549-991-5